Anixa Biosciences Inc

ANIX

Company Profile

  • Business description

    Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

  • Contact

    3150 Almaden Expressway
    Suite 250
    San JoseCA95118
    USA

    T: +1 408 708-9808

    https://www.anixa.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 October 2026

    Employees

    4

Stocks News & Analysis

stocks

Cheap e-commerce share continues sales momentum

The e-commerce business continues its sales momentum despite challenging backdrop.
stocks

Chart of the Week: Booming mined commodity prices see little value on offer

Iran War disruptions drive thermal coal and aluminum prices higher but value to be found in other pockets.
stocks

3 ASX top picks to combat inflation

The mechanics behind inflation resilient ASX businesses.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,945.2066.700.75%
CAC 408,207.8934.780.43%
DAX 4025,177.807.09-0.03%
Dow JONES (US)50,644.28182.600.36%
FTSE 10010,505.0113.620.13%
HKSE25,328.23271.22-1.06%
NASDAQ26,674.7318.550.07%
Nikkei 22564,999.413.320.01%
NZX 50 Index13,244.9417.130.13%
S&P 5007,520.361.240.02%
S&P/ASX 2008,717.7065.500.76%
SSE Composite Index4,093.7351.65-1.25%

Market Movers